References

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statis tics, 1998. CA Cancer J Clin 1998;48:6-29.

2. Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993;119:914-23.

3. Goldstein MM, Messing EM. Prostate and bladder cancer screening. J Am Coll Surg 1998;186:63-74.

4. Brawley OW. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 1997;80:1857-63.

5. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate-specific antigen-based screening. J Urol 1994;152:1732-6.

6. Andriole GL, Catalona WJ. Using PSA to screen for prostate cancer: the Washington University experience. Urol Clin North Am 1993;20:647-51.

7. Douglas TH, McLeod DG, Mostofi FK, et al. Prostate-spe cific antigen-detected prostate cancer (stage T1c): an analysis of whole mount prostatectomy specimens. Prostate 1997;32:59-64.

8. Collins MM, Barry MJ. Controversies in prostate cancer screening: analogies to the early lung cancer screening debate. JAMA 1996;276:1976-9.

9. Stein B, Lindenmayer JM. Proposed prostate cancer screen ing recommendations. Med Health RI 1997;80:343-5.

10. Arcangeli CG, Ornstein DK, Keetch DW, Andriole GL.

Prostate-specific antigen as a screening test for prostate cancer: the United States experience. Urol Clin North Am 1997;24:299-306.

11. Coley CM, Barry MJ, Mulley AG. Early detection of prostate cancer. Part III: screening for prostate cancer. Ann Intern Med 1997;126:480-4.

12. DeAntoni EP. Eight years of "Prostate Cancer Awareness

Week": lessons in screening and early detection. Cancer 1997;80:1845-51.

13. Vanchieri C. Prostate cancer screening trials: fending off critics to recruit men. J Natl Cancer Inst 1998;90:10-2.

14. Chodak GW, Keller P, Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal examination. J Urol 1989;141:1136-8.

15. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994;151:1283-90.

16. Thompson IM, Ernst JJ, Gangai MP, Spencer CR.

Adenocarcinoma of the prostate: results of routine urological screening. J Urol 1984;132:690-2.

17. Smith DS, Catalona WJ. Interexaminer variability of digi tal rectal examination in detecting prostate cancer. Urology 1995;45:70-4.

18. Gerber GS, Thompson IM, Thisted R, Chodak GW.

Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 1993;269:61-4.

19. Bretton PR. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study. South Med J 1994;87:720-3.

20. Brawer MK, Chetner MP, Beatie J, et al. Screening for pro-

static carcinoma with prostate-specific antigen. J Urol 1992;147:841-5.

21. Babaian RJ, Dinney CP, Ramirez EI, Evans RB. Diagnostic testing for prostate cancer detection: less is best. Urology 1993;41:421-5.

22. Christensson A, Laurell C, Lilja H. Enzymatic activity of the prostate-specific antigen and its relation with extracellular serine protease inhibitors. Eur J Biochem 1990;194:755-63.

23. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.

24. Mettlin C, Lee F, Drago J, Murphy JP. Findings on the early detection of prostate cancer in 2425 men. Cancer 1991; 67:2949-58.

25. Labrie F, Dupont A, Suburu R, et al. Serum prostate-spe cific antigen as a pre-screening test for prostate cancer. J Urol 1992;147:846-52.

26. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-54.

27. Stamey TA, Yang N, Hay AR, et al. Prostate-specific anti gen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.

28. Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate-specific antigen levels. J Urol 1995;154:407-13.

29. Herschman JD, Smith DS, Catalona WJ. Effect of ejacula tion on serum total and free prostate-specific antigen concentrations. Urology 1997;50:239-43.

30. Stenner J, Holthaus K, Mackenzie SH, Crawford ED. The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population. Urology 1998; 51:455-9.

31. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate-specific antigen: review of available data. J Urol 1996;155:3-9.

32. Andriole GL, Walsh PC, Epstein JI, et al. Treatment with finasteride preserves the usefulness of PSA in prostate cancer (CaP) detection. J Urol 1998;159 Suppl: 277.

33. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate-specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152:2037-42.

34. Brawer MK, Lange PH. Prostate-specific antigen: its role in early detection, staging, and monitoring of prostatic carcinoma. J Endourol 1989;3:227-36.

35. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.

36. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996;276:1309-15.

37. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng per mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-5.

38. Benson MC, Whang IS, Olsson CA, et al. The use of prostate-specific antigen density to enhance the predictive value of intermediate levels of serum-prostate specific antigen. J Urol 1992;147:817-21.

39. Seaman E, Whang M, Olsson CA, et al. PSA density: role in patient evaluation and management. Urol Clin North Am 1993;20:653-63.

40. Smith DS, Catalona WJ, Keetch DW. Comparison of per cent free PSA and PSA density as methods to enhance the specificity of PSA screening. J Urol 1996;155 Suppl: 422A.

41. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal eval uation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.

42. Smith DS, Catalona WJ. Rate of change of serum prostate-

specific antigen levels as a method for prostate cancer detection. J Urol 1994;152:1163-7.

43. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-

specific reference ranges for serum prostate-specific antigen in men 60 years old or older. J Urol 1995;153:1160-3.

44. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:860-4.

45. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.

46. Woodrum DL, Brawer MK, Partin AW, et al. Interpre tation of free prostate-specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5-12.

47. Luderer AA, Chen Y, Soriano TF, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187-94.

48. Catalona WJ, Partin AW, Slawin KM, et al. Use of the per centage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 1998;279:1542-7.

49. Babaian RJ, Fritsche HA, Zhang Z, et al. Evaluation of

ProstAsure index in the detection of prostate cancer: a preliminary report. Urology 1998;51:132-6.

50. Wingo PA, Landis S, Ries LAG. An adjustment to the 1997

estimate for new prostate cancer cases. Cancer 1997;80: 1810-3.

51. Pototsky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.

52. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995; 274:1445-9.

53. Polednak AP. Trends in prostate carcinoma incidence in

Connecticut (1988 to 1994) by age and race. Cancer 1997;79:99-103.

54. Stephenson RA, Smart CR, Mineau GP, et al. The fall in incidence of prostate carcinoma: on the downside of a prostate-specific antigen induced peak in incidence— data from the Utah cancer registry. Cancer 1995;77: 1342-8.

55. Merrill RM, Potosky AL, Feuer EJ. Changing trends in U.S.

prostate cancer incidence rates. J Natl Cancer Inst 1996;88:1683-5.

56. Labrie F, Candas B, Cusan L, et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996;47:212-7.

57. Mettlin C, Murphy GP, Lee F, et al. Characteristics of prostate cancers detected in a multimodality early detection program. Cancer 1993;72:1701-8.

58. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate-specific antigen-based screening. J Urol 1994;152:1732-6.

59. Ohori M, Wheeler TM, Dunn JK, et al. The pathological features and prognosis of prostate cancer detected with current diagnostic tests. J Urol 1994;152:1714-20.

60. Stamey TA, Kabalin JN, McNeal JE, et al. Prostate-specific antigen in the diagnosis and treatment of adenocarci-noma of the prostate. II. Radical prostatectomy-treated patients. J Urol 1989;141:1076-83.

61. Humphrey PA, Keetch DW, Smith DS, et al. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate-specific antigen-based screening. J Urol 1996;155:816-20.

62. Scaletscky R, Koch MO, Eckstein CW, et al. Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate-specific antigen. J Urol 1994;152: 129-31.

63. Gann PH. Interpreting recent trends in prostate cancer incidence and mortality. Epidemiology 1997;8:117-20.

64. Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the Surveillance, Epidemiology, and End Results program. Cancer 1997;80:1835-44.

65. Smart CR. Prostate cancer facts and fiction. J Surg Oncol

1997;66:223-9.

66. Shalala DE. Cancer death rate decline for the first time ever in the 1990s [press release]. Bethesda (MD): National Cancer Institute; 1996.

67. Brawley OW. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 1997;80:1857-63.

68. Standaert B, Denis L. The European randomized study of screening for prostate cancer: an update. Cancer 1997; 80:1830-4.

69. Optenberg SA, Thompson IM. Economics of screening for carcinoma of the prostate. Urol Clin North Am 1990; 17:719-37.

70. Lubke WL, Optenberg SA, Thompson IM. Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States. J Natl Cancer Inst 1994;86:1790-2.

71. Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993;119:914-23.

72. Benoit RM, Naslund MJ. The economics of prostate can cer screening. Oncology 1997;11:1533-43.

73. Chodak GM. The Benoit and Naslund article reviewed.

Oncology 1997;11:1543.

74. Littrup PJ. Future benefits and cost-effectiveness of prostate carcinoma screening. Cancer 1997;80:1864-70.

0 0

Post a comment